Crescent Biopharma

Crescent Biopharma is a clinical-stage biotechnology company developing next-generation targeted therapies for solid tumors. Scientifically, they focus on engineering innovative biologics, including PD-1 x VEGF bispecific antibodies (like lead candidate CR-001) designed to simultaneously block tumor blood supply and boost the immune response. They are also building a pipeline of novel antibody-drug conjugates (ADCs) to deliver potent treatments directly to cancer cells.